SML0472
4-IPP
≥97% (HPLC)
Synonyma:
4-Iodo-6-phenylpyrimidine
Přihlásitk zobrazení cen stanovených pro organizaci a smluvních cen
About This Item
Empirický vzorec (Hillův zápis):
C10H7IN2
Číslo CAS:
Molekulová hmotnost:
282.08
MDL number:
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
Doporučené produkty
Quality Level
assay
≥97% (HPLC)
form
powder
color
white to beige
solubility
DMSO: 10 mg/mL (clear solution, warmed)
storage temp.
−20°C
SMILES string
Ic1cc(ncn1)-c2ccccc2
InChI
1S/C10H7IN2/c11-10-6-9(12-7-13-10)8-4-2-1-3-5-8/h1-7H
InChI key
ZTCJXHNJVLUUMR-UHFFFAOYSA-N
Application
4-IPP has been used as a macrophage migration inhibitory factor (MIF) in conditioned medium (CM) for in vitro migration assay.
Biochem/physiol Actions
4-IPP is a cell permeable, potent macrophage migration inhibitory factor (MIF) antagonist that covalently modifies MIF N-terminal proline.
4-IPP is a cell permeable, potent macrophage migration inhibitory factor (MIF) antagonist.
4-Iodo-6-phenylpyrimidine (4-IPP) has the potential to be a new anti-polyploid therapeutic agent that may be utilized in patients with thyroid cancer to target polyploid tumor cells. It suppresses osteoclastogenesis by blocking the IMF-κB pathway. 4-IPP can be employed as a therapeutic target for macrophage migration inhibitory factor (MIF) to treat pathologic osteolytic bone diseases and postmenopausal bone loss. It can prevent the development and motility of lung adenocarcinoma cells and can stimulate apoptosis and mitotic death of thyroid carcinomas.
Storage Class
11 - Combustible Solids
wgk_germany
WGK 3
Vyberte jednu z posledních verzí:
Osvědčení o analýze (COA)
Lot/Batch Number
Nevidíte správnou verzi?
Potřebujete-li konkrétní verzi, můžete vyhledat daný certifikát podle čísla dávky nebo čísla šarže.
Již tento produkt vlastníte?
Dokumenty související s produkty, které jste v minulosti zakoupili, byly za účelem usnadnění shromážděny ve vaší Knihovně dokumentů.
Zákazníci si také prohlíželi
Sarah Maria Johler et al.
Cancer immunology, immunotherapy : CII, 65(12), 1465-1476 (2016-09-16)
Macrophage migration inhibitory factor (MIF) is known to be involved in oncogenic transformation, tumour progression, and immunosuppression and is overexpressed in many solid tumours, including paediatric rhabdomyosarcoma (RMS). We investigated the function of MIF in RMS during treatment with cytotoxic
Tali Lang et al.
Nature communications, 9(1), 2223-2223 (2018-06-10)
Macrophage migration inhibitory factor (MIF) exerts multiple effects on immune cells, as well as having functions outside the immune system. MIF can promote inflammation through the induction of other cytokines, including TNF, IL-6, and IL-1 family cytokines. Here, we show
Nadège Kindt et al.
Journal of clinical medicine, 8(1) (2019-01-13)
Human papilloma virus (HPV) infection has been well-established as a risk factor in head and neck squamous cell carcinoma (HNSCC). The carcinogenic effect of HPV is mainly due to the E6 and E7 oncoproteins, which inhibit the functions of p53
Kavitha Yaddanapudi et al.
Cancer immunology research, 4(2), 101-112 (2015-11-26)
Highly aggressive cancers "entrain" innate and adaptive immune cells to suppress antitumor lymphocyte responses. Circulating myeloid-derived suppressor cells (MDSC) constitute the bulk of monocytic immunosuppressive activity in late-stage melanoma patients. Previous studies revealed that monocyte-derived macrophage migration inhibitory factor (MIF)
Hiro Takahashi et al.
PloS one, 8(10), e78250-e78250 (2013-10-30)
The diagnosis and treatment of soft tissue sarcomas (STSs) has been particularly difficult, because STSs are a group of highly heterogeneous tumors in terms of histopathology, histological grade, and primary site. Recent advances in genome technologies have provided an excellent
Náš tým vědeckých pracovníků má zkušenosti ve všech oblastech výzkumu, včetně přírodních věd, materiálových věd, chemické syntézy, chromatografie, analytiky a mnoha dalších..
Obraťte se na technický servis.